What do TFPI antagonists offer that current treatments don't?
TFPI (tissue factor pathway inhibitor) is a natural brake on blood clotting. In hemophilia, the clotting cascade is already impaired, so blocking TFPI with an antibody can help restore enough clotting to prevent bleeds. This mechanism works regardless of whether the patient has inhibitors (antibodies that neutralize factor replacement), which is a major advantage because inhibitor patients often have limited options. Marstacimab and concizumab are two such antibodies in clinical trials.
In the phase 3 BASIS trial, once-weekly subcutaneous marstacimab reduced annualized bleeding rates (ABR) by 91.6% compared with on-demand therapy and was superior to routine prophylaxis (35.2% reduction) in patients without inhibitors [1]. This means patients went from frequent bleeds to near-normal levels—many had zero bleeds. Concizumab, given once daily subcutaneously, also reduced bleeding in phase 2 trials across hemophilia A and B, including those with inhibitors, with estimated ABRs around 4.8–6.4 [5]. These are not just small improvements; they represent a paradigm shift from intravenous factor infusions to simple subcutaneous shots.
What's the catch? Safety and limitations
The main concern with any pro-coagulant therapy is the risk of blood clots. Across the marstacimab clinical program, no thromboembolic events were reported in over 28 months of continuous treatment [2]. Similarly, concizumab trials reported no thromboembolic events [5]. However, these are relatively short-term data, and the trials are not yet large enough to rule out rare clotting risks. Injection site reactions were common but mild—about 11% with marstacimab—and anti-drug antibodies developed in about 20% of patients, but they were low-titer and transient, with no clinical impact [1][2].
Another limitation is that these agents are not a cure; they require ongoing injections. Also, while they reduce bleeds, they may not achieve the same high sustained factor levels as some newer factor replacement therapies like efanesoctocog alfa, which can maintain near-normal factor VIII activity for most of the week [3][4]. For patients who prioritize very high trough levels, factor replacement might still be preferred. But for those who struggle with intravenous infusions or have inhibitors, TFPI antagonists offer a practical, effective alternative.
Who benefits most from TFPI antagonism?
Patients with hemophilia B with inhibitors have the highest unmet need, and concizumab received Breakthrough Therapy designation from the FDA for this group [6]. The mechanism of TFPI antagonism is independent of factor VIII or IX, so it should work equally well in hemophilia A and B, with or without inhibitors. The phase 3 BASIS trial included both hemophilia A and B patients without inhibitors and showed consistent efficacy across both types [1]. For inhibitor patients, who often rely on bypassing agents that can be less effective or carry thrombosis risk, TFPI antagonists could be a game-changer.
However, the evidence is still evolving. The phase 2 concizumab trials included inhibitor patients and showed significant bleed reduction compared with on-demand treatment [5]. But the phase 3 marstacimab data presented here focused on patients without inhibitors [1]. So while the mechanism suggests broad applicability, the strongest data so far are in non-inhibitor patients. Ongoing phase 3 trials for concizumab are specifically evaluating inhibitor patients [5][6].
About These Sources
This answer is built on 6 peer-reviewed studies — published from 2021 to 2024, 1 from 2024 or later, 6 in Q1 journals, collectively cited 279 times — selected as the most relevant from 10 studies that passed quality screening, drawn from 50 papers retrieved from a database of over 500 million.
Sources used in this answer
Efficacy and Safety of the Anti-Tissue Factor Pathway Inhibitor Marstacimab in Participants with Severe Hemophilia without Inhibitors: Results from the Phase 3 Basis Trial
In the phase 3 BASIS trial, once-weekly subcutaneous marstacimab reduced annualized bleeding rates by 91.6% vs on-demand and was superior to routine prophylaxis (35.2% reduction) in 116 patients with severe hemophilia A/B without inhibitors, with no thromboembolic events.
Marstacimab, an Anti-Tissue Factor Pathway Inhibitor, in Participants with Hemophilia Α or B, with and without Inhibitors: An Integrated Analysis of Safety
Integrated safety analysis of marstacimab across phase 1b/2 and phase 3 programs (144 patients, up to 28 months) found no thromboembolic events, low rates of mild injection site reactions (11.2%), and transient anti-drug antibodies in 20.5% of patients.
Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A
In a phase 3 trial of 74 children with severe hemophilia A, once-weekly efanesoctocog alfa (a factor VIII replacement) achieved zero median annualized bleeding rate and no inhibitor development, with factor VIII activity >40 IU/dL for 3 days.
Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A
In a phase 3 trial of 133 adults with severe hemophilia A, once-weekly efanesoctocog alfa reduced annualized bleeding rate to 0.71 and was superior to prestudy prophylaxis, with no inhibitor development.
Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
In phase 2 extension trials, once-daily subcutaneous concizumab reduced annualized bleeding rates to 4.8–6.4 across hemophilia A/B with and without inhibitors, with no thromboembolic events and transient anti-drug antibodies in 25% of patients.
Concizumab: a novel anti-TFPI therapeutic for hemophilia
Concizumab is a subcutaneous anti-TFPI therapy that rebalances hemostasis and is expected to be equally effective in hemophilia A and B regardless of inhibitor status; it received FDA Breakthrough Therapy designation for hemophilia B with inhibitors.